Clinical trials: Antipsychotic Agents
Weight Gain
A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme
Olanzapine is an atypical antipsychotic agent indicated for the treatment of schizophrenia and moderate to severe manic episode. Olanzapine is among the many antipsychotic agents associated with weight gain .
- Trial name
- NCT00191828
- Testing
- olanzapine
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Psychosis
Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis
The purpose of this study is to help understand if by adding Niaspan FCT (study drug) to antipsychotic medications will it help maintain or improve cognitve functioning.
- Trial name
- NCT01720095
- Testing
- Niaspan
- Where
- Canada
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority
Schizophrenia, Psychotic Disorders
A Clinical Trial on the Antipsychotic Properties of Cannabidiol
The purpose of this study is to determine whether cannabidiol, a herbal cannabinoid, is effective in the treatment of acute schizophrenic or schizophreniform psychosis in a placebo-controlled, randomized double-blind study.
- Trial name
- NCT00309413
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- University of Cologne
Schizophrenia, Psychotic Disorders
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis
The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment for individuals suffering from…
- Trial name
- PAFIP2 (NCT02305823)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Comparing Antipsychotic Medications in LBD Over Time
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or…
- Trial name
- CAMELOT (NCT05590637)
- Testing
- Pimavanserin, Quetiapine
- Where
- 2 sites in United States
- Volunteers
- 94 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Depressive Disorder, Depressive Disorder, Major
A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression
The purpose of this study is to evaluate the effectiveness and safety of risperidone to augment SSRI therapy in patients with treatment-resistant depression and to demonstrate the long-term maintenance effect of risperidone as…
- Conditions
- Depressive Disorder, Depressive Disorder, Major, Depression
- Trial name
- NCT00044681
- Testing
- risperidone
- Volunteers
- 258 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Psychotic Disorders
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
This study will test the effectiveness of two different treatments for children and adolescents who have gained weight on their antipsychotic medications.
- Trial name
- IMPACT (NCT00806234)
- Testing
- Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Johns Hopkins University
Overweight, Autism Spectrum Disorder
Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
The purpose of this study is to determine whether metformin is safe and effective in the treatment of weight or weight gain in young people with Autism Spectrum Disorders (ASD) who are currently taking atypical antipsychotic…
- Trial name
- MET (NCT01825798)
- Testing
- Metformin
- Where
- 4 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Holland Bloorview Kids Rehabilitation Hospital
Psychosis, Agitation
Ziprasidone vs Standard Therapy for Agitated Patients in the ED
The primary objective is to determine if ziprasidone is superior to standard therapies in the emergency department treatment of the acutely agitated patient.
- Conditions
- Psychosis, Agitation, Delirium
- Trial name
- NCT00786318
- Testing
- ziprasidone, Standard therapy
- Where
- United States
- Sponsor
- George Washington University
Weight, Body
Long-term Antipsychotic Pediatric Safety Trial
Main LAP01 study: The purpose is to evaluate the long-term pathologic weight changes associated with multi-year risperidone or aripiprazole therapy in 3 - <18-year-old children, who have varying durations of prior antipsychotic…
- Trial name
- LAPS (NCT03522168)
- Testing
- Risperidone, Aripiprazole
- Where
- 37 sites in United States
- Volunteers
- 509 people
- Sponsor
- Duke University
Depressive Disorder, Major
Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder
The primary objective is to examine changes in pre/post-augmentation healthcare costs and resource utilization in patients diagnosed with major depressive disorder (MDD) who augment their current antidepressant therapy with an…
- Trial name
- NCT01145313
- Volunteers
- 501 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment With Antipsychotics
Antipsychotics are approved to treat several conditions, including Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, and Major Depressive Disorder among others.
- Trial name
- NCT02573168
- Testing
- GeneSight Psychotropic (GEN), Enhanced-GeneSight Psychotropic (E-GEN), Treatment as Usual (TAU)
- Where
- Canada
- Volunteers
- 103 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Schizophrenia, Schizoaffective Disorder
24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study
Ziprasidone is recommended to be dosed twice daily for the treatment of schizophrenia, based on peripheral pharmacokinetics and a knowledge of its half life in plasma level (5-10 hours).
- Trial name
- NCT00818298
- Testing
- ziprazidone
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Impaired Cognition
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
- Trial name
- NCT01716975
- Testing
- EVP-6124
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 767 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
Fingolimod in Schizophrenia Patients
This will be a single site safety and proof of concept study conducted at the Indiana University Psychotic Disorders Program. Forty subjects with schizophrenia or schizoaffective disorders will be randomized 1:1 to double-blind…
- Trial name
- STEP (NCT01779700)
- Testing
- Fingolimod
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Indiana University
Autistic Disorder, Autism
A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
The purpose of this study is to evaluate the effectiveness (change in level of irritability and related behaviors) and safety and tolerability of the administration of 2 different fixed dose levels of risperidone (an atypical…
- Trial name
- NCT00576732
- Testing
- Risperidone high dose, Risperidone low dose
- Where
- 20 sites in United States
- Volunteers
- 96 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychotic Disorders
Bergen Psychosis Project 2 - The Best Intro Study
In the Bergen Psychosis Project 2 the antipsychotic drugs aripiprazole, amisulpride, and olanzapine will be compared head-to-head in patients with schizophrenia and related psychoses and followed for 12 months.
- Trial name
- BP2 (NCT01446328)
- Testing
- Amisulpride, Aripiprazole, Olanzapine
- Where
- 4 sites in Austria, Norway
- Volunteers
- 151 people
- Sponsor
- Haukeland University Hospital
Schizophrenia
Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI
The general aim is to compare the effects of typical and atypical antipsychotic medication on brain structure and function. A parallel group treatment trial will be utilized to compare the effects of the typical antipsychotic…
- Trial name
- NCT01234454
- Testing
- Risperidone, Olanzapine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia
The purpose of this study is to explore tolerability, safety and effectiveness of flexibly dosed paliperidone extended release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- PERFlexS (NCT00460512)
- Testing
- Paliperidone ER
- Where
- 231 sites in Belgium, Bulgaria and 20 more
- Volunteers
- 1,814 people
- Sponsor
- Janssen-Cilag International NV
Bipolar Depression
What is the Antidepressant Mechanism of Action of Quetiapine in Bipolar Depression?
PURPOSE The purpose of this study is to elucidate whether quetiapine fumurate (Seroquel) exerts its antidepressant activity in bipolar disorder through altering either serotonergic or catecholinergic activity.
- Trial name
- NCT00817323
- Testing
- Dietary amino-acid depletion
- Sponsor
- University of British Columbia